AACR Abstract 5583/15 Peg-ADA2 for CLL is HALO's 1
Post# of 36
(Total Views: 754)
Posted On: 04/02/2017 5:36:28 PM
AACR Abstract 5583/15 Peg-ADA2 for CLL is HALO's 1st venture into CLL - Roche's territory- challenged by TGTX - Halo has targeted only solid cancer as a primary target till now. If this program pans out - even more of a reason for Roche to buy HALO. HALO also has a partnered trial w ADRO's LADD @AACR potentiaiong T cell I/O.
(0)
(0)Halozyme Therapeutics (HALO) Stock Research Links
Scroll down for more posts ▼